Plain English with Derek Thompson The Future of GLP-1 Drugs and AI Medicine, With Eli Lilly CEO David Ricks
170 snips
Feb 24, 2026 
David Ricks, CEO of Eli Lilly and a leader steering GLP-1 drug development, discusses the science behind incretin drugs and how weight-loss effects were discovered. He explains why these medicines affect appetite, inflammation, and behavior. They cover business impacts on Lilly, R&D strategies, next-gen drug and delivery plans, public distrust of pharma, and AI’s role in drug discovery.
AI Snips
Chapters
Transcript
Episode notes
How A Gila Monster Led To Modern GLP-1 Drugs
- Eli Lilly traced GLP-1 drug progress from 1970s incretin research to a Gila monster-derived peptide turned diabetes drug in 2006.
- Lilly engineered longer-acting peptides (once-weekly) to reduce GI side effects and make weight-loss dosing feasible.
GLP-1 Drugs Produce Broad Metabolic And Anti-Inflammatory Effects
- GLP-1 drugs act as a system-level regulator that reduces appetite, improves insulin sensitivity, and lowers inflammation across organs.
- Lilly saw 92% less diabetes over three years on tirzepatide and rapid HS-CRP drops of 50–70%, suggesting metabolic and inflammatory mechanisms.
GLP-1s May Reduce Addiction And Compulsive Behaviors
- Patients report reduced nonfood cravings (tobacco, alcohol, gambling) on GLP-1s, implying central nervous system effects beyond satiety.
- Rodent studies show reduced nicotine desire and neurotransmitter changes, and Lilly is running prospective trials for addiction disorders.